Horizon Pharma Prices Secondary Offering Of 11.66 Mln Shares At $12.05/Shr

(RTTNews) - Horizon Pharma plc (HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced the pricing of a previously announced underwritten secondary offering of 11.66 million of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and would not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering may close on or about November 19, 2014.

Morgan Stanley, Citigroup, Cowen and Company and Jefferies are acting as joint book-running managers for this offering. JMP Securities is acting as financial advisor for this offering.